title: Vancomycin dosing and monitoring 2 years after the guidelines.
abstract: Administration of vancomycin continues to be common despite perceived concerns of increased MICs, treatment failures and toxicity. In 2009, a consensus guideline was published in an effort to optimize dosing and monitoring of this useful agent. It was unique in targeting a specific antibiotic rather than a disease state or organism. However, a lack of prospective randomized double-blinded trials upon which to base guidelines was noted. In addition, several questions were raised and remain unanswered. Since guideline publication, new data has added to our understanding of the implications of aggressive dosing and subsequent monitoring. The following article discusses research published within the last 2 years.
authors.affiliation: Albany Medical Center Hospital, Department of Pharmacy, Albany, NY 12208, USA. lomaesb@mail.amc.edu
authors.forename: Ben M
authors.initials: BM
authors.lastname: Lomaestro
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D054796:Drug Dosage Calculations; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology; D008826:Microbial Sensitivity Tests; D017410:Practice Guidelines as Topic; D051437:Renal Insufficiency / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D017211:Treatment Failure; D014640:Vancomycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin